1098 related articles for article (PubMed ID: 9580626)
1. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
Donnelly-Roberts DL; Puttfarcken PS; Kuntzweiler TA; Briggs CA; Anderson DJ; Campbell JE; Piattoni-Kaplan M; McKenna DG; Wasicak JT; Holladay MW; Williams M; Arneric SP
J Pharmacol Exp Ther; 1998 May; 285(2):777-86. PubMed ID: 9580626
[TBL] [Abstract][Full Text] [Related]
2. (+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.
Sullivan JP; Decker MW; Brioni JD; Donnelly-Roberts D; Anderson DJ; Bannon AW; Kang CH; Adams P; Piattoni-Kaplan M; Buckley MJ
J Pharmacol Exp Ther; 1994 Nov; 271(2):624-31. PubMed ID: 7965777
[TBL] [Abstract][Full Text] [Related]
3. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
Arneric SP; Sullivan JP; Briggs CA; Donnelly-Roberts D; Anderson DJ; Raszkiewicz JL; Hughes ML; Cadman ED; Adams P; Garvey DS
J Pharmacol Exp Ther; 1994 Jul; 270(1):310-8. PubMed ID: 7518514
[TBL] [Abstract][Full Text] [Related]
4. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.
Sullivan JP; Donnelly-Roberts D; Briggs CA; Anderson DJ; Gopalakrishnan M; Piattoni-Kaplan M; Campbell JE; McKenna DG; Molinari E; Hettinger AM; Garvey DS; Wasicak JT; Holladay MW; Williams M; Arneric SP
Neuropharmacology; 1996 Jun; 35(6):725-34. PubMed ID: 8887981
[TBL] [Abstract][Full Text] [Related]
5. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
Sullivan JP; Donnelly-Roberts D; Briggs CA; Anderson DJ; Gopalakrishnan M; Xue IC; Piattoni-Kaplan M; Molinari E; Campbell JE; McKenna DG; Gunn DE; Lin NH; Ryther KB; He Y; Holladay MW; Wonnacott S; Williams M; Arneric SP
J Pharmacol Exp Ther; 1997 Oct; 283(1):235-46. PubMed ID: 9336329
[TBL] [Abstract][Full Text] [Related]
6. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
Gopalakrishnan M; Monteggia LM; Anderson DJ; Molinari EJ; Piattoni-Kaplan M; Donnelly-Roberts D; Arneric SP; Sullivan JP
J Pharmacol Exp Ther; 1996 Jan; 276(1):289-97. PubMed ID: 8558445
[TBL] [Abstract][Full Text] [Related]
7. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
Bannon AW; Decker MW; Curzon P; Buckley MJ; Kim DJ; Radek RJ; Lynch JK; Wasicak JT; Lin NH; Arnold WH; Holladay MW; Williams M; Arneric SP
J Pharmacol Exp Ther; 1998 May; 285(2):787-94. PubMed ID: 9580627
[TBL] [Abstract][Full Text] [Related]
8. Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells.
Puttfarcken PS; Manelli AM; Arneric SP; Donnelly-Roberts DL
J Neurochem; 1997 Sep; 69(3):930-8. PubMed ID: 9282914
[TBL] [Abstract][Full Text] [Related]
9. Gene targeting demonstrates that alpha4 nicotinic acetylcholine receptor subunits contribute to expression of diverse [3H]epibatidine binding sites and components of biphasic 86Rb+ efflux with high and low sensitivity to stimulation by acetylcholine.
Marks MJ; Meinerz NM; Drago J; Collins AC
Neuropharmacology; 2007 Sep; 53(3):390-405. PubMed ID: 17631923
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
Gerzanich V; Peng X; Wang F; Wells G; Anand R; Fletcher S; Lindstrom J
Mol Pharmacol; 1995 Oct; 48(4):774-82. PubMed ID: 7476906
[TBL] [Abstract][Full Text] [Related]
11. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats.
Boyce S; Webb JK; Shepheard SL; Russell MGN; Hill RG; Rupniak NMJ
Pain; 2000 Apr; 85(3):443-450. PubMed ID: 10781917
[TBL] [Abstract][Full Text] [Related]
12. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains.
Warpman U; Nordberg A
Neuroreport; 1995 Nov; 6(17):2419-23. PubMed ID: 8747166
[TBL] [Abstract][Full Text] [Related]
13. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.
Holladay MW; Wasicak JT; Lin NH; He Y; Ryther KB; Bannon AW; Buckley MJ; Kim DJ; Decker MW; Anderson DJ; Campbell JE; Kuntzweiler TA; Donnelly-Roberts DL; Piattoni-Kaplan M; Briggs CA; Williams M; Arneric SP
J Med Chem; 1998 Feb; 41(4):407-12. PubMed ID: 9484491
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex.
Zhang X; Gong ZH; Fasth KJ; Långström B; Nordberg A
Neurochem Int; 1998; 32(5-6):435-41. PubMed ID: 9676742
[TBL] [Abstract][Full Text] [Related]
15. Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.
Parker MJ; Beck A; Luetje CW
Mol Pharmacol; 1998 Dec; 54(6):1132-9. PubMed ID: 9855644
[TBL] [Abstract][Full Text] [Related]
16. Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain.
Kesingland AC; Gentry CT; Panesar MS; Bowes MA; Vernier JM; Cube R; Walker K; Urban L
Pain; 2000 May; 86(1-2):113-8. PubMed ID: 10779668
[TBL] [Abstract][Full Text] [Related]
17. The heterocyclic substituted pyridine derivative (+/-)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors.
Bencherif M; Schmitt JD; Bhatti BS; Crooks P; Caldwell WS; Lovette ME; Fowler K; Reeves L; Lippiello PM
J Pharmacol Exp Ther; 1998 Mar; 284(3):886-94. PubMed ID: 9495846
[TBL] [Abstract][Full Text] [Related]
18. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current.
Alkondon M; Albuquerque EX
J Pharmacol Exp Ther; 1995 Aug; 274(2):771-82. PubMed ID: 7543571
[TBL] [Abstract][Full Text] [Related]
19. Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells.
Riganti L; Matteoni C; Di Angelantonio S; Nistri A; Gaimarri A; Sparatore F; Canu-Boido C; Clementi F; Gotti C
Br J Pharmacol; 2005 Dec; 146(8):1096-109. PubMed ID: 16273122
[TBL] [Abstract][Full Text] [Related]
20. Characterization of [3H]ABT-418: a novel cholinergic channel ligand.
Anderson DJ; Williams M; Pauly JR; Raszkiewicz JL; Campbell JE; Rotert G; Surber B; Thomas SB; Wasicak J; Arneric SP
J Pharmacol Exp Ther; 1995 Jun; 273(3):1434-41. PubMed ID: 7791118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
